Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Phase 3Active, not recruiting
- Sponsor
- Alumis Inc.
- Start
- Jan 2025
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of envudeucitinib in plaque psoriasis, sponsored by Alumis Inc.. Started Jan 2025; status: active, not recruiting.
02
Drugs
envudeucitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06846541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846541.